vs
Amphastar Pharmaceuticals, Inc.（AMPH）とTG THERAPEUTICS, INC.（TGTX）の財務データ比較。上の社名をクリックして会社を切り替えられます
TG THERAPEUTICS, INC.の直近四半期売上が大きい（$192.6M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.1倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 12.0%、差は1.4%）。TG THERAPEUTICS, INC.の前年同期比売上増加率が高い（78.0% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $19.6M）。過去8四半期でTG THERAPEUTICS, INC.の売上複合成長率が高い（74.2% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
TGセラピューティクスは商業段階のバイオ医薬品企業で、B細胞悪性腫瘍、自己免疫疾患、神経変性疾患の患者向け革新的治療薬の開発・販売に注力している。主力製品は標的モノクローナル抗体や経口低分子薬で、主な市場は北米と欧州だ。
AMPH vs TGTX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $192.6M |
| 純利益 | $24.4M | $23.0M |
| 粗利率 | 46.8% | 80.2% |
| 営業利益率 | 19.4% | 26.2% |
| 純利益率 | 13.3% | 12.0% |
| 売上前年比 | -1.8% | 78.0% |
| 純利益前年比 | -35.7% | -1.3% |
| EPS（希薄化後） | $0.51 | $0.14 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $192.6M | ||
| Q3 25 | $191.8M | $161.7M | ||
| Q2 25 | $174.4M | $141.1M | ||
| Q1 25 | $170.5M | $120.9M | ||
| Q4 24 | $186.5M | $108.2M | ||
| Q3 24 | $191.2M | $83.9M | ||
| Q2 24 | $182.4M | $73.5M | ||
| Q1 24 | $171.8M | $63.5M |
| Q4 25 | $24.4M | $23.0M | ||
| Q3 25 | $17.4M | $390.9M | ||
| Q2 25 | $31.0M | $28.2M | ||
| Q1 25 | $25.3M | $5.1M | ||
| Q4 24 | $38.0M | $23.3M | ||
| Q3 24 | $40.4M | $3.9M | ||
| Q2 24 | $37.9M | $6.9M | ||
| Q1 24 | $43.2M | $-10.7M |
| Q4 25 | 46.8% | 80.2% | ||
| Q3 25 | 51.4% | 82.6% | ||
| Q2 25 | 49.6% | 86.6% | ||
| Q1 25 | 50.0% | 87.1% | ||
| Q4 24 | 46.5% | 85.8% | ||
| Q3 24 | 53.3% | 88.9% | ||
| Q2 24 | 52.2% | 88.7% | ||
| Q1 24 | 52.4% | 91.4% |
| Q4 25 | 19.4% | 26.2% | ||
| Q3 25 | 13.2% | 18.2% | ||
| Q2 25 | 24.2% | 24.7% | ||
| Q1 25 | 21.9% | 7.1% | ||
| Q4 24 | 24.2% | 27.7% | ||
| Q3 24 | 29.8% | 14.8% | ||
| Q2 24 | 30.3% | 12.0% | ||
| Q1 24 | 27.9% | -14.6% |
| Q4 25 | 13.3% | 12.0% | ||
| Q3 25 | 9.0% | 241.7% | ||
| Q2 25 | 17.8% | 20.0% | ||
| Q1 25 | 14.8% | 4.2% | ||
| Q4 24 | 20.4% | 21.6% | ||
| Q3 24 | 21.1% | 4.6% | ||
| Q2 24 | 20.8% | 9.4% | ||
| Q1 24 | 25.1% | -16.9% |
| Q4 25 | $0.51 | $0.14 | ||
| Q3 25 | $0.37 | $2.43 | ||
| Q2 25 | $0.64 | $0.17 | ||
| Q1 25 | $0.51 | $0.03 | ||
| Q4 24 | $0.74 | $0.16 | ||
| Q3 24 | $0.78 | $0.02 | ||
| Q2 24 | $0.73 | $0.04 | ||
| Q1 24 | $0.81 | $-0.07 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $142.0M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $648.0M |
| 総資産 | $1.6B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $142.0M | ||
| Q3 25 | $276.2M | $131.6M | ||
| Q2 25 | $231.8M | $251.9M | ||
| Q1 25 | $236.9M | $276.2M | ||
| Q4 24 | $221.6M | $311.0M | ||
| Q3 24 | $250.5M | $341.0M | ||
| Q2 24 | $217.8M | $217.3M | ||
| Q1 24 | $289.6M | $209.8M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $648.0M | ||
| Q3 25 | $776.7M | $607.2M | ||
| Q2 25 | $757.5M | $276.4M | ||
| Q1 25 | $751.3M | $237.3M | ||
| Q4 24 | $732.3M | $222.4M | ||
| Q3 24 | $727.7M | $192.2M | ||
| Q2 24 | $713.3M | $177.6M | ||
| Q1 24 | $672.4M | $160.1M |
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.7B | $1.0B | ||
| Q2 25 | $1.6B | $702.6M | ||
| Q1 25 | $1.6B | $656.7M | ||
| Q4 24 | $1.6B | $577.7M | ||
| Q3 24 | $1.5B | $586.0M | ||
| Q2 24 | $1.5B | $401.2M | ||
| Q1 24 | $1.6B | $373.3M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $19.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $19.6M |
| FCFマージンFCF / 売上 | 13.4% | 10.2% |
| 設備投資強度設備投資 / 売上 | 4.5% | 0.0% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 0.85× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $-25.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $19.7M | ||
| Q3 25 | $52.6M | $-23.2M | ||
| Q2 25 | $35.6M | $7.4M | ||
| Q1 25 | $35.1M | $-28.7M | ||
| Q4 24 | $29.0M | $-25.6M | ||
| Q3 24 | $60.0M | $-12.2M | ||
| Q2 24 | $69.1M | $5.5M | ||
| Q1 24 | $55.3M | $-8.2M |
| Q4 25 | $24.6M | $19.6M | ||
| Q3 25 | $47.2M | $-23.2M | ||
| Q2 25 | $25.0M | $7.4M | ||
| Q1 25 | $24.4M | $-28.7M | ||
| Q4 24 | $16.6M | $-25.7M | ||
| Q3 24 | $46.2M | $-12.2M | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | 10.2% | ||
| Q3 25 | 24.6% | -14.4% | ||
| Q2 25 | 14.3% | 5.2% | ||
| Q1 25 | 14.3% | -23.8% | ||
| Q4 24 | 8.9% | -23.7% | ||
| Q3 24 | 24.1% | -14.6% | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | 0.0% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 7.2% | 0.0% | ||
| Q2 24 | 3.3% | 0.0% | ||
| Q1 24 | 5.1% | 0.0% |
| Q4 25 | 1.35× | 0.85× | ||
| Q3 25 | 3.03× | -0.06× | ||
| Q2 25 | 1.15× | 0.26× | ||
| Q1 25 | 1.39× | -5.67× | ||
| Q4 24 | 0.76× | -1.10× | ||
| Q3 24 | 1.48× | -3.15× | ||
| Q2 24 | 1.82× | 0.80× | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
TGTX
| Products | $189.1M | 98% |
| License | $3.5M | 2% |
